Watch for the PDUFA date on February 4, 2027, and any AdCom announcement. Also monitor the MAA submission timeline and potential partnership or commercialization updates ahead of launch.
Price Chart
Executive Summary
BridgeBio announced FDA acceptance of its NDA for oral infigratinib in achondroplasia with Priority Review and a PDUFA date of February 4, 2027. The Phase 3 PROPEL 3 trial met its primary endpoint (AHV +2.10 cm/yr, p<0.0001) and key secondary endpoints, including the first statistically significant improvement in body proportionality in an achondroplasia Phase 3 trial. This is a major regulatory milestone for a potential first-in-class oral therapy targeting a significant unmet need.
Key Facts
- FDA accepted NDA for oral infigratinib with Priority Review; PDUFA target date February 4, 2027
- Phase 3 PROPEL 3 met primary endpoint: AHV treatment effect +2.10 cm/yr (p<0.0001)
- First achondroplasia Phase 3 trial to show statistically significant improvement in body proportionality (ages 3–8, p<0.05) and arm span z-score (+0.37 SD, p<0.0001)
- Oral infigratinib was well tolerated with no discontinuations or serious adverse events related to study drug
- BridgeBio plans to submit MAA to EMA in Q4 2026 and is prepared for U.S. launch upon approval
- Oral infigratinib holds Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations from FDA
Financial Impact
Potential first-in-class oral therapy for achondroplasia, affecting ~55,000 patients in U.S. and EU; no revenue or deal value stated in filing
Risk Factors
- FDA may not approve by PDUFA date or may require additional data
- Competition from existing injectable therapies (e.g., vosoritide) could limit market share
- Long-term safety and efficacy data beyond 52 weeks are not yet available
- Commercial launch execution risk for a novel oral therapy in a rare disease
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375352 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $68.25 | awaiting T+20 | — | $69.37 (+1.64%) |
Oct 22, 2026 5d ago | Press Release | $68.12 | awaiting T+20 | — | $69.37 (+1.84%) |
Oct 13, 2026 14d ago | 8-K | $63.30 | awaiting T+20 | — | $69.37 (+9.59%) |
Oct 6, 2026 21d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.14 | awaiting T+20 | — | $69.37 (+4.88%) |
Sep 18, 2026 5w ago | Press Release | $66.58 $67.94 | ▲ +2.04% | ▲ +2.95% | $69.37 (+4.19%) |
Aug 31, 2026 8w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $69.37 (−9.43%) |
Aug 26, 2026 8w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $69.37 (−12.60%) |
Aug 22, 2026 9w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $69.37 (−14.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers